预测阿尔茨海默病的进展使用一个多功能序列-长度-自适应编码器-解码器LSTM架构
IEEE journal of biomedical and health informatics
|April 9, 2024
概括
这项研究引入了一种适应性深度学习模型,用于预测阿尔茨海默病 (AD) 的进展. 序列长度自适应编码器-解码器长短期记忆模型通过更多的患者数据提高了准确性,有助于早期干预.
科学领域:
- 神经学 神经学
- 人工智能的人工智能
- 医疗信息学 医疗信息学
背景情况:
- 早期和准确的阿尔茨海默病 (AD) 检测对于有效的治疗和管理至关重要.
- 在单个时间点使用现有的诊断分数和临床状态来预测疾病进展仍然具有挑战性.
- 目前用于AD检测的深度学习模型往往缺乏稳定性,因为对纵向数据的适应训练不足.
研究的目的:
- 开发一种自适应的深度学习模型,在六年内预测个体阿尔茨海默病诊断状态.
- 通过整合纵向患者数据来提高预测性能,每次额外的患者访问都会得到改善.
- 在现实临床环境中解决非适应性深度学习模型的局限性.
主要方法:
- 开发一个序列长度自适应编码器-解码器长短期存储器 (SLA-ED LSTM) 模型.
- 使用来自阿尔茨海默病神经成像计划 (ADNI) 档案的纵向数据.
- 动态调整解码器LSTM以适应可变的训练和推理序列长度.
主要成果:
- 该SLA-ED LSTM模型显示了高的预测准确性.
- 对于一个推断长度为1,一个连续长度为9次访问的序列长度产生了最高的平均测试准确度 (0.920) 和AUC (0.982).
- 该模型在预测疾病进展方面显著超过了最先进的方法.
结论:
- 大约9次患者访问的纵向数据足以捕捉有意义的认知变化,以准确预测AD进展.
- 拟议的SLA-ED LSTM模型为早期阿尔茨海默病检测和进展预测提供了稳定和改进的方法.
- 这种适应性深度学习策略有望提高阿尔茨海默病管理中的临床决策.
更多相关视频
相关概念视频
01:26Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
01:35Long-term Potentiation
55.2K
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
55.2K
01:22Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
01:30Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113